Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

  • Moreno-Manuel, Andrea
  • Simoes, Ines
  • Aranda, Fernando
  • Calabuig-Fariñas, Silvia
  • Carreras, Esther
  • Zuñiga, Sheila
  • Saenger, Yvone
  • Rosell, Rafael
  • Camps-Herrero, Carlos
  • Lozano, Francisco
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
[EN] Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6¿two lymphocyte surface markers involved in the fine tuning of TCR signaling¿as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC). Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC. Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, P=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher CD5/CD4+ ratio had significantly improved prognosis. Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early stages of NSCLC (HR=0.554; 95% CI, 0.360¿0.853; P=0.007). Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and CD6 expression¿ although CD6 expression alone did not reach significant prognostic value in our NSCLC training cohort. Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance., This work was supported by Spanish Health Institute Carlos III (ISCII, Fondo de Investigacion Sanitaria; PI15-00753 to RS and P118/00226 to EJ and CC), Spanish Ministry of Economy, Industry and Competitiveness (MINECO, Plan Nacional de I+D+i; SAF2016-80535-R to FL) -co-financed by European Development Regional Fund "A way to achieve Europe" ERDF; Worldwide Cancer Research (14-1275 to FL), Fundacio La Marato TV3 (201319-30-31-32 to FL and YS), and Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya (2017/SGR/1582 to FL). AM is recipient of a PhD scholarship from Asociacion Espanola Contra el Cancer (AECC) Scientific Foundation and Junta Provincial Asociada de Valencia AECC; IS, FA and EC are recipients of fellowships from Fundacao para a Ciencia e a Tecnologia (SFRH/BD/75738/2011), Sara Borrell Program from ISCIII (CD15/00016), and European Community Seventh Framework Program (BIOTRACK, FP7/2007/2013; 229673), respectively.